Omeros Corp financial data

Symbol
OMER on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Elliott Avenue West, Seattle, WA
State of incorporation
WA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 309 % +8.47%
Return On Equity 118 %
Return On Assets -45.3 % -88.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.1M shares +0.21%
Common Stock, Shares, Outstanding 58M shares -5.05%
Entity Public Float 225M USD -31.5%
Common Stock, Value, Issued 580K USD -5.07%
Weighted Average Number of Shares Outstanding, Basic 58.2M shares -7.28%
Weighted Average Number of Shares Outstanding, Diluted 62.8M shares +0.17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 120M USD +4.05%
General and Administrative Expense 48.2M USD -6.42%
Costs and Expenses 169M USD +2.87%
Operating Income (Loss) -169M USD -2.87%
Net Income (Loss) Attributable to Parent -157M USD -33.1%
Earnings Per Share, Basic -2.7 USD/shares -43.6%
Earnings Per Share, Diluted 0.65 USD/shares -79.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.4M USD -52.1%
Cash, Cash Equivalents, and Short-term Investments 90.1M USD -47.6%
Assets, Current 134M USD -38.4%
Property, Plant and Equipment, Net 2.68M USD +37.3%
Operating Lease, Right-of-Use Asset 15M USD -19.7%
Assets 277M USD -26.8%
Accounts Payable, Current 5.91M USD -23.4%
Employee-related Liabilities, Current 8.87M USD +20.2%
Accrued Liabilities, Current 26M USD -18.4%
Liabilities, Current 79.5M USD +49.2%
Operating Lease, Liability, Noncurrent 12.2M USD -29.8%
Retained Earnings (Accumulated Deficit) -910M USD -20.8%
Stockholders' Equity Attributable to Parent -183M USD -631%
Liabilities and Equity 277M USD -26.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.8M USD -124%
Net Cash Provided by (Used in) Financing Activities 98.4M USD
Net Cash Provided by (Used in) Investing Activities -61.9M USD +65.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 58M shares -5.05%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.27M USD +26.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.6M USD -53.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.15M USD -9.85%
Deferred Tax Assets, Valuation Allowance 284M USD +19.1%
Deferred Tax Assets, Gross 324M USD +14.8%
Operating Lease, Liability 17.5M USD
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 58K USD
Lessee, Operating Lease, Liability, to be Paid 20.2M USD -29%
Property, Plant and Equipment, Gross 13.8M USD +12.8%
Operating Lease, Liability, Current 5.24M USD +14.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.14M USD +0.79%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.91M USD -18.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.72M USD -57.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.12M USD -10.9%
Deferred Tax Assets, Operating Loss Carryforwards 80.4M USD -15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 4.46M USD +127%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 1.82M USD +1.97%
Additional Paid in Capital 727M USD -0.11%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 204K USD +9.68%
Share-based Payment Arrangement, Expense 10.5M USD -9.93%
Interest Expense 28.6M USD -9.85%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%